Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems

Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems

Human castration-resistant prostate cancer (CRPC) is a significant target of clinical research. The use of DNA-damaging agents has a long history in cancer chemotherapy but is limited by their toxicities. The combination with a safer drug can be a strategy in reducing dosage and toxicity while incre...

Full description

Bibliographic Details
Main Authors: Jo-Fan Chang, Jui-Ling Hsu, Yi-Hua Sheng, Wohn-Jenn Leu, Chia-Chun Yu, She-Hung Chan, Mei-Ling Chan, Lih-Ching Hsu, Shih-Ping Liu, Jih-Hwa Guh
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-01-01
Series:Frontiers in Oncology
Subjects:
phosphodiesterase type 5 inhibitor
PDE5-independent
topoisomerase II inhibitor
homologous recombination DNA repair
non-homologous end joining DNA repair
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2018.00681/full

Similar Items

Similar Items